美国FDA于2011年2月25日批准Edarbi(有效成分为azilsartan medoxomil)片剂用于成年人治疗高血压。临床研究结果显示,与其他2种获得FDA批准的降压药Diovan(valsartan)和Benicar(olmesartan)相比,Edarbi能更有效地全天候降低血压。血压指心脏对血管内的血液对于血管壁的压力,如果血压升高并一直持续高压,会对身体产生多种不良影响。在美 US FDA approved Edarbi (azilsartan medoxomil) tablets on February 25, 2011 for the treatment of hypertension in adults. Clinical studies have shown that Edarbi reduces blood pressure more effectively around the clock than the other two FDA-approved antihypertensives, Diovan (valsartan) and Benicar (olmesartan). Blood pressure refers to the pressure exerted by the heart on the blood vessel wall in the blood vessel. If the blood pressure is increased and sustained high pressure, it will have various adverse effects on the body. In the United States